Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
From Promise to Therapy
Join The Seattle Genetics Team
We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More
Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma More
Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia More
Seattle Genetics At A Glance
|Global Headquarters||Bothell, WA|
|Number of Employees||1,000+|
|Clinical & preclinical pipeline programs||12+|
|ADCs in clinical trials using our technology||20+|
“…we seek to improve the lives of people with cancer.” – Clay Siegall · 9 hours ago